Phase 1, first-in-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature

被引：11
|
作者：
Tolcher, Anthony W.
Alley, Evan W.
Chichili, Guru
Baughman, Jan E.
Moore, Paul A.
Bonvini, Ezio
Vasselli, James Robert
Wigginton, Jon M.
Powderly, John D.
机构：
[1] START San Antonio, San Antonio, TX USA
[2] Univ Pennsylvania, Philadelphia, PA USA
[3] MacroGenics Inc, Rockville, MD USA
[4] MacroGenics Inc, Bethesda, MD USA
[5] MacroGenics Inc, Frederick, MD USA
[6] Carolina BioOncol Inst, Huntersville, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS3105
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3105
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase 1, open label, dose escalation study of MGD009, a humanized B7-H3 x CD3 DART protein, in combination with MGA012, an anti-PD-1 antibody, in patients with relapsed or refractory B7-H3-expressing tumors.
    Shankar, Sadhna
    Spira, Alexander I.
    Strauss, James
    Liu, Liqin
    La Motte-Mohs, Ross
    Wu, Tony
    Johnson, Syd
    Bonvini, Ezio
    Moore, Paul A.
    Wigginton, Jon M.
    Vasselli, Jim
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [2] A novel B7-H3 x CD3 bispecific T-cell engager for the treatment of B7-H3+ tumors
    Li, Feng
    Liu, Ming
    Hua, Yanan
    Wei, Xuemei
    Qin, Luying
    Cao, Guangcan
    Yang, Daniel Chunxu
    Zhang, Wenjun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
    Picarda, Elodie
    Ohaegbulam, Kim C.
    Zang, Xingxing
    CLINICAL CANCER RESEARCH, 2016, 22 (14) : 3425 - 3431
  • [4] A phase 1 study of enoblituzumab in combination with pembrolizumab in patients with advanced B7-H3-expressing cancers
    Rizvi, Naiyer A.
    Loo, Deryk
    Baughman, Jan E.
    Yun, Soyoung
    Chen, Francine
    Moore, Paul A.
    Bonvini, Ezio
    Vasselli, James Robert
    Wigginton, Jon M.
    Cohen, Roger B.
    Aggarwal, Charu
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [5] Novel conditionally active tetravalent B7-H3 x CD3 T-cell engagers targeting solid tumors
    Cugnetti, Ana Paula
    Liu, Haizhen
    McNeeley, Patricia
    Woodard, Kathryn
    Chang, Cathy
    Frey, Gerhard
    Boyle, William J.
    Short, Jay M.
    CANCER RESEARCH, 2024, 84 (06)
  • [6] B7-H3 & PD-L1 double-humanized BALB/c mouse: a novel animal model for preclinical studies of human B7-H3 antibodies or bispecific antibodies
    Guo, Shiying
    Song, Lingyu
    Qin, Xin
    Xu, Jianming
    Sun, Hongyan
    Ju, Cunxiang
    Wang, Hongyu
    Chen, Santi Suryani
    Li, Zhiying
    Moore, Mark Wade
    Zhao, Jing
    Gao, Xiang
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Tumor B7-H3 (CD276) expression and survival of patients with pancreatic cancer
    Inamura, Kentaro
    Yokouchi, Yusuke
    Kobayashi, Maki
    Inoue, Yosuke
    Saiura, Akio
    Takazawa, Yutaka
    Ishikawa, Yuichi
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Targeting immunotherapy for bladder cancer using anti-CD3x B7-H3 bispecific antibody
    Ma, Wanru
    Ma, Juan
    Ma, Ping
    Lei, Ting
    Zhao, Man
    Zhang, Man
    CANCER MEDICINE, 2018, 7 (10): : 5167 - 5177
  • [9] A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.
    Desantes, Kenneth
    Maris, John M.
    McDowell, Kimberly
    Mackall, Crystal
    Shankar, Sadhna
    Vasselli, Jim
    Chen, Francine
    Loo, Deryk
    Moore, Paul A.
    Wigginton, Jon M.
    Sonde, Paul M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients
    Baral, Aparajita
    Ye, Hong Xing
    Jiang, Pu Cha
    Yao, Yu
    Mao, Ying
    ONCOLOGY LETTERS, 2014, 8 (03) : 1195 - 1201
12345